董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 郑伟 | 男 | Chief Executive Officer and Director | 60 | 未披露 | 648.75 | 2024-04-16 |
| 陈侃 | 男 | Director | 42 | 未披露 | 未持股 | 2024-04-16 |
| 潘武宾 | 男 | President and Chairperson of the Board | 59 | 未披露 | 672.83 | 2024-04-16 |
| Jean Liu | 女 | Director | 55 | 未披露 | 7.09 | 2024-04-16 |
| Karen J. Wilson | 女 | Director | 60 | 未披露 | 14.18 | 2024-04-16 |
| James Zuie chin Huang | 男 | Director | 58 | 未披露 | 未持股 | 2024-04-16 |
| Kleanthis G. Xanthopoulos | 男 | Lead Independent Director | 64 | 未披露 | 13.88 | 2024-04-16 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| 郑伟 | 男 | Chief Executive Officer and Director | 60 | 未披露 | 648.75 | 2024-04-16 |
| Steven Chan | 男 | Chief Financial Officer | 52 | 未披露 | 22.50 | 2024-04-16 |
| 潘武宾 | 男 | President and Chairperson of the Board | 59 | 未披露 | 672.83 | 2024-04-16 |
董事简历
中英对照 | 中文 | 英文- 郑伟
-
郑伟是互联生物制药控股有限公司的联合创始人，自2012年成立以来一直担任互联生物制药控股有限公司首席执行官和董事会成员。在此之前，郑伟博士于2007年12月至2011年3月在Arena制药公司担任免疫学主任，负责监督其免疫学发现项目。在此之前，郑伟博士于1998年4月至2007年9月在ChemoCentryx公司担任科学家和项目负责人。在担任这一职务之前，郑伟博士是Glycomed公司的一名科学家，Glycomed公司于1992年9月至1995年11月被Ligand制药公司收购。在加入Glycomed，Inc.之前，郑伟博士还在斯坦福大学医学院进行免疫学研究，郑伟博士在加州大学戴维斯分校获得生物化学和分子生物学博士学位，在华南师范大学获得生物学学士学位。
Zheng Wei,is a co-founder of the company and has served as Connect Biopharma Holdings Limited Chief Executive Officer and a member of Connect Biopharma Holdings Limited board of directors since Connect Biopharma Holdings Limited inception in 2012. Prior to that, Dr. Wei was Director of Immunology at Arena Pharmaceuticals, Inc. from December 2007 to March 2011, where he oversaw its immunology discovery programs. Prior to this role, Dr. Wei was a scientist and program leader at ChemoCentryx, Inc. from April 1998 to September 2007. Prior to this role, Dr. Wei was a scientist at Glycomed, Inc. (acquired by Ligand Pharmaceuticals Incorporated) from September 1992 to November 1995. Before joining Glycomed, Inc., Dr. Wei also conducted immunology research at Stanford University School of Medicine. Dr. Wei received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis and his bachelor's degree in Biology from South China Normal University. - 郑伟是互联生物制药控股有限公司的联合创始人，自2012年成立以来一直担任互联生物制药控股有限公司首席执行官和董事会成员。在此之前，郑伟博士于2007年12月至2011年3月在Arena制药公司担任免疫学主任，负责监督其免疫学发现项目。在此之前，郑伟博士于1998年4月至2007年9月在ChemoCentryx公司担任科学家和项目负责人。在担任这一职务之前，郑伟博士是Glycomed公司的一名科学家，Glycomed公司于1992年9月至1995年11月被Ligand制药公司收购。在加入Glycomed，Inc.之前，郑伟博士还在斯坦福大学医学院进行免疫学研究，郑伟博士在加州大学戴维斯分校获得生物化学和分子生物学博士学位，在华南师范大学获得生物学学士学位。
- Zheng Wei,is a co-founder of the company and has served as Connect Biopharma Holdings Limited Chief Executive Officer and a member of Connect Biopharma Holdings Limited board of directors since Connect Biopharma Holdings Limited inception in 2012. Prior to that, Dr. Wei was Director of Immunology at Arena Pharmaceuticals, Inc. from December 2007 to March 2011, where he oversaw its immunology discovery programs. Prior to this role, Dr. Wei was a scientist and program leader at ChemoCentryx, Inc. from April 1998 to September 2007. Prior to this role, Dr. Wei was a scientist at Glycomed, Inc. (acquired by Ligand Pharmaceuticals Incorporated) from September 1992 to November 1995. Before joining Glycomed, Inc., Dr. Wei also conducted immunology research at Stanford University School of Medicine. Dr. Wei received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis and his bachelor's degree in Biology from South China Normal University.
- 陈侃
-
陈侃自2020年12月起担任互联生物制药控股有限公司董事会成员。陈博士是Qiming Weichuang创业投资管理上海有限公司的负责人，自2016年2月起在Qiming Weichuang任职，专注于医疗保健投资。陈博士还分别自2020年8月，2020年4月和2020年2月起担任Zion Pharma Limited、Kira Pharmaceuticals和Abbisko Therapeutics的董事会成员。2014年10月至2016年1月，陈博士是强生公司的高级科学家，在此之前，陈博士是江苏恒瑞医药的集团负责人，陈博士在哈佛医学院完成免疫学博士后培训，在凯斯西储大学获得细胞生物学博士学位，在复旦大学获得生物科学学士学位。
Kan Chen,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020. Dr. Chen is currently a partner and previously a principal at Qiming Weichuang Venture Capital Management (Shanghai) Co. Ltd., where he has served with a focus on healthcare investment since February 2016. Dr. Chen has also served on the boards of directors of Antengene Corporation Limited, CANbridge Pharmaceuticals Inc. and Zion Pharma Limited since March 2021, December 2020 and August 2020, respectively, and he served as a director of Abbisko Cayman Limited from February 2020 to June 2021. From October 2014 to January 2016, Dr. Chen was a senior scientist at Johnson & Johnson, where he focused on cancer medicine. Prior to that, Dr. Chen was a group leader at Jiangsu Hengrui Medicine, where he specialized in cancer immunotherapies. Dr. Chen completed his postdoctoral training in immunology at Harvard Medical School, earned his Ph.D. in Cell Biology from Case Western Reserve University and earned his B.S. in Biological Sciences from Fudan University. - 陈侃自2020年12月起担任互联生物制药控股有限公司董事会成员。陈博士是Qiming Weichuang创业投资管理上海有限公司的负责人，自2016年2月起在Qiming Weichuang任职，专注于医疗保健投资。陈博士还分别自2020年8月，2020年4月和2020年2月起担任Zion Pharma Limited、Kira Pharmaceuticals和Abbisko Therapeutics的董事会成员。2014年10月至2016年1月，陈博士是强生公司的高级科学家，在此之前，陈博士是江苏恒瑞医药的集团负责人，陈博士在哈佛医学院完成免疫学博士后培训，在凯斯西储大学获得细胞生物学博士学位，在复旦大学获得生物科学学士学位。
- Kan Chen,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020. Dr. Chen is currently a partner and previously a principal at Qiming Weichuang Venture Capital Management (Shanghai) Co. Ltd., where he has served with a focus on healthcare investment since February 2016. Dr. Chen has also served on the boards of directors of Antengene Corporation Limited, CANbridge Pharmaceuticals Inc. and Zion Pharma Limited since March 2021, December 2020 and August 2020, respectively, and he served as a director of Abbisko Cayman Limited from February 2020 to June 2021. From October 2014 to January 2016, Dr. Chen was a senior scientist at Johnson & Johnson, where he focused on cancer medicine. Prior to that, Dr. Chen was a group leader at Jiangsu Hengrui Medicine, where he specialized in cancer immunotherapies. Dr. Chen completed his postdoctoral training in immunology at Harvard Medical School, earned his Ph.D. in Cell Biology from Case Western Reserve University and earned his B.S. in Biological Sciences from Fudan University.
- 潘武宾
-
潘武宾是互联生物制药控股有限公司的联合创始人，自2012年5月起担任互联生物制药控股有限公司总裁兼董事会主席。此前，潘博士于2006年6月至2011年10月共同创立并领导了由风险投资支持的合同研究机构Crown Bioscience Inc.。在此任职期间，曾在公司担任多个高管领导职务，包括中国区总裁、首席运营官和执行副总裁，在此之前，潘博士曾于2000年11月至2006年5月在青岛远兴生物制药有限公司担任副总裁。在此之前，潘博士曾于1996年10月至2000年10月在Cubist Pharmaceuticals收购的Terragen Discovery Inc.担任研究科学家。潘博士在苏塞克斯大学获得生物化学博士学位，并在加州大学柏克莱分校完成博士后训练，拥有清华大学硕士学位、中山大学药理学硕士学位和动物学学士学位。
Wubin Pan,is a co-founder of the company and has served as Connect Biopharma Holdings Limited President and Chairperson of Connect Biopharma Holdings Limited board of directors since May 2012. Previously, Dr. Pan co-founded and led Crown Bioscience Inc., a venture-backed contract research organization, from June 2006 to October 2011. During this tenure, he served in various executive leadership positions at the company, including PRC President, Chief Operation Officer and Executive Vice President. Prior to this role, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. from November 2000 to May 2006. Prior to that, Dr. Pan worked as a research scientist with TerraGen Discovery Inc. (acquired by Cubist Pharmaceuticals) from October 1996 to October 2000. Dr. Pan obtained his Ph.D. in Biochemistry from University of Sussex and completed postdoctoral training at the University of California at Berkeley. He holds an M.B.A. from Tsing-Hua University and an M.S. in Pharmacology and a B.S. in Zoology, both from Sun Yat-sen University. - 潘武宾是互联生物制药控股有限公司的联合创始人，自2012年5月起担任互联生物制药控股有限公司总裁兼董事会主席。此前，潘博士于2006年6月至2011年10月共同创立并领导了由风险投资支持的合同研究机构Crown Bioscience Inc.。在此任职期间，曾在公司担任多个高管领导职务，包括中国区总裁、首席运营官和执行副总裁，在此之前，潘博士曾于2000年11月至2006年5月在青岛远兴生物制药有限公司担任副总裁。在此之前，潘博士曾于1996年10月至2000年10月在Cubist Pharmaceuticals收购的Terragen Discovery Inc.担任研究科学家。潘博士在苏塞克斯大学获得生物化学博士学位，并在加州大学柏克莱分校完成博士后训练，拥有清华大学硕士学位、中山大学药理学硕士学位和动物学学士学位。
- Wubin Pan,is a co-founder of the company and has served as Connect Biopharma Holdings Limited President and Chairperson of Connect Biopharma Holdings Limited board of directors since May 2012. Previously, Dr. Pan co-founded and led Crown Bioscience Inc., a venture-backed contract research organization, from June 2006 to October 2011. During this tenure, he served in various executive leadership positions at the company, including PRC President, Chief Operation Officer and Executive Vice President. Prior to this role, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. from November 2000 to May 2006. Prior to that, Dr. Pan worked as a research scientist with TerraGen Discovery Inc. (acquired by Cubist Pharmaceuticals) from October 1996 to October 2000. Dr. Pan obtained his Ph.D. in Biochemistry from University of Sussex and completed postdoctoral training at the University of California at Berkeley. He holds an M.B.A. from Tsing-Hua University and an M.S. in Pharmacology and a B.S. in Zoology, both from Sun Yat-sen University.
- Jean Liu
-
Jean Liu ，自2021年8月起担任董事会成员。Liu 女士是全球多产品生物技术公司Seagen Inc.的首席法律官，自2014年以来一直在该公司任职。此前，Liu 女士曾担任Halozyme Therapeutics，Inc.的副总法律顾问，以及Durect Corporation的首席法律官和公司秘书。在职业生涯早期，Liu 女士曾担任Pillsbury，Madison&Sutro LLP律师事务所的律师，现为Pillsbury Winthrop Shaw Pittman LLP律师事务所和风险投资法律集团律师，为技术转让、许可、专利以及版权和商标诉讼提供咨询。Liu 女士在密歇根大学获得细胞生物学和分子生物学学士学位，来自斯坦福大学的生物学硕士，哥伦比亚大学的J.D.。
Jean Liu,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2021. Ms. Liu was the Chief Legal Officer at Seagen Inc., a global, multi-product biotechnology company, which was acquired by Pfizer in December 2023, where she has served since 2014. Previously, Ms. Liu served as the Vice President of General Counsel at Halozyme Therapeutics, Inc. and as the Chief Legal Officer and Corporate Secretary at Durect Corporation. Earlier in her career, Ms. Liu was an attorney at Pillsbury, Madison & Sutro LLP (now Pillsbury Winthrop Shaw Pittman LLP) and Venture Law Group, where she advised on technology transfer, licensing, patents, and copyright and trademark litigation. Ms. Liu holds a B.S. in Cellular and Molecular Biology from the University of Michigan, an M.S. in Biology from Stanford University, and a J.D. from Columbia University. - Jean Liu ，自2021年8月起担任董事会成员。Liu 女士是全球多产品生物技术公司Seagen Inc.的首席法律官，自2014年以来一直在该公司任职。此前，Liu 女士曾担任Halozyme Therapeutics，Inc.的副总法律顾问，以及Durect Corporation的首席法律官和公司秘书。在职业生涯早期，Liu 女士曾担任Pillsbury，Madison&Sutro LLP律师事务所的律师，现为Pillsbury Winthrop Shaw Pittman LLP律师事务所和风险投资法律集团律师，为技术转让、许可、专利以及版权和商标诉讼提供咨询。Liu 女士在密歇根大学获得细胞生物学和分子生物学学士学位，来自斯坦福大学的生物学硕士，哥伦比亚大学的J.D.。
- Jean Liu,has served as a member of Connect Biopharma Holdings Limited board of directors since August 2021. Ms. Liu was the Chief Legal Officer at Seagen Inc., a global, multi-product biotechnology company, which was acquired by Pfizer in December 2023, where she has served since 2014. Previously, Ms. Liu served as the Vice President of General Counsel at Halozyme Therapeutics, Inc. and as the Chief Legal Officer and Corporate Secretary at Durect Corporation. Earlier in her career, Ms. Liu was an attorney at Pillsbury, Madison & Sutro LLP (now Pillsbury Winthrop Shaw Pittman LLP) and Venture Law Group, where she advised on technology transfer, licensing, patents, and copyright and trademark litigation. Ms. Liu holds a B.S. in Cellular and Molecular Biology from the University of Michigan, an M.S. in Biology from Stanford University, and a J.D. from Columbia University.
- Karen J. Wilson
-
Karen J. Wilson，自2021年3月起担任非执行董事。她目前在Angion Biomedica、Connect Biopharma和Vaxart, Inc.等多家上市公司的董事会任职。Wilson女士曾担任Jazz Pharmaceuticals plc财务高级副总裁，直至2020年9月，此前曾担任财务副总裁兼首席会计官。在2011年2月加入爵士制药之前，Wilson女士曾在PDL BioPharma, Inc.担任财务副总裁兼首席会计官。她之前还曾担任Wilson Crisler LLC咨询公司的负责人、ViroLogic公司的首席财务官、Novare Surgical Systems公司的首席财务官和运营副总裁，以及德勤会计师事务所的顾问和审计师。Wilson女士是一名注册会计师，在加州大学伯克利分校获得商学学士学位。
Karen J. Wilson,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020. Ms. Wilson is also currently a member of the boards of directors of Elicio Therapeutics, Inc. (formerly Angion Biomedica) and LAVA Therapeutics B.V. Ms. Wilson also served as a member of the board of directors of Vaxart, Inc. between August 2020 to August 2022. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. from 2009 to January 2011. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. - Karen J. Wilson，自2021年3月起担任非执行董事。她目前在Angion Biomedica、Connect Biopharma和Vaxart, Inc.等多家上市公司的董事会任职。Wilson女士曾担任Jazz Pharmaceuticals plc财务高级副总裁，直至2020年9月，此前曾担任财务副总裁兼首席会计官。在2011年2月加入爵士制药之前，Wilson女士曾在PDL BioPharma, Inc.担任财务副总裁兼首席会计官。她之前还曾担任Wilson Crisler LLC咨询公司的负责人、ViroLogic公司的首席财务官、Novare Surgical Systems公司的首席财务官和运营副总裁，以及德勤会计师事务所的顾问和审计师。Wilson女士是一名注册会计师，在加州大学伯克利分校获得商学学士学位。
- Karen J. Wilson,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020. Ms. Wilson is also currently a member of the boards of directors of Elicio Therapeutics, Inc. (formerly Angion Biomedica) and LAVA Therapeutics B.V. Ms. Wilson also served as a member of the board of directors of Vaxart, Inc. between August 2020 to August 2022. Ms. Wilson served as Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer. Prior to joining the Jazz Pharmaceuticals organization in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. from 2009 to January 2011. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.
- James Zuie chin Huang
-
James Zuie chin Huang，拥有超过30年的生物技术经验，是Panacea Venture的创始人和管理合伙人，这是一家专注于生命科学的投资公司，专注于全球创新和变革的早期和成长期医疗保健和生命科学公司的投资。加入Panacea之前，他曾担任Kleiner Perkins （KPCB） China的管理合伙人和Vivo Ventures（专门从事生命科学投资的风险投资公司）的管理合伙人。他还曾担任Anesiva, Inc.（一家专注于疼痛管理治疗的生物制药公司）的总裁。在职业生涯早期，他曾在Tularik Inc.（被Amgen Inc.收购）、GlaxoSmithKline LLC、Bristol-Myers Squibb Company和ALZA Corp.（被Johnson & Johnson收购）担任业务开发、销售、营销和研发方面的高级职位。此外，他曾担任Casi Pharmaceuticals, Inc.（2013年4月至2023年4月），Windtree Therapeutics, Inc.（2018年12月至2023年4月）和Alaunos Therapeutics, Inc.（2020年7月至2023年9月）的董事会成员。目前，他担任多家公司的董事会董事，包括kinstar Globalgene Technology, Inc. （9960.HK）。他获得Stanford Graduate School of Business的工商管理硕士学位和the University of California, Berkeley的化学工程学士学位。
James Zuie chin Huang,has served as a member of Connect Biopharma Holdings Limited board of directors since February 12, 2024. Mr. Huang is the Founding Managing Partner of Panacea Venture, a life science focused investment firm with a focus on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Prior to Panacea, Mr. Huang was Managing Partner at Kleiner Perkins (KPCB) China and a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. He was also the president of Anesiva, Inc., a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior roles in business development, sales, marketing, and R&D with Tularik Inc. (acquired by Amgen Inc.), GlaxoSmithKline LLC, Bristol-Myers Squibb Company and ALZA Corp. (acquired by Johnson & Johnson). Additionally, Mr. Huang served on the board of directors of Casi Pharmaceuticals, Inc. from April 2013 to April 2023, Windtree Therapeutics, Inc. from December 2018 to April 2023 and Alaunos Therapeutics, Inc. from July 2020 to September 2023. Currently, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Globalgene Technology, Inc. (9960.HK). He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley. - James Zuie chin Huang，拥有超过30年的生物技术经验，是Panacea Venture的创始人和管理合伙人，这是一家专注于生命科学的投资公司，专注于全球创新和变革的早期和成长期医疗保健和生命科学公司的投资。加入Panacea之前，他曾担任Kleiner Perkins （KPCB） China的管理合伙人和Vivo Ventures（专门从事生命科学投资的风险投资公司）的管理合伙人。他还曾担任Anesiva, Inc.（一家专注于疼痛管理治疗的生物制药公司）的总裁。在职业生涯早期，他曾在Tularik Inc.（被Amgen Inc.收购）、GlaxoSmithKline LLC、Bristol-Myers Squibb Company和ALZA Corp.（被Johnson & Johnson收购）担任业务开发、销售、营销和研发方面的高级职位。此外，他曾担任Casi Pharmaceuticals, Inc.（2013年4月至2023年4月），Windtree Therapeutics, Inc.（2018年12月至2023年4月）和Alaunos Therapeutics, Inc.（2020年7月至2023年9月）的董事会成员。目前，他担任多家公司的董事会董事，包括kinstar Globalgene Technology, Inc. （9960.HK）。他获得Stanford Graduate School of Business的工商管理硕士学位和the University of California, Berkeley的化学工程学士学位。
- James Zuie chin Huang,has served as a member of Connect Biopharma Holdings Limited board of directors since February 12, 2024. Mr. Huang is the Founding Managing Partner of Panacea Venture, a life science focused investment firm with a focus on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide. Prior to Panacea, Mr. Huang was Managing Partner at Kleiner Perkins (KPCB) China and a Managing Partner at Vivo Ventures, a venture capital firm specializing in life sciences investments. He was also the president of Anesiva, Inc., a biopharmaceutical company focused on pain-management treatments. Earlier in his career, he held senior roles in business development, sales, marketing, and R&D with Tularik Inc. (acquired by Amgen Inc.), GlaxoSmithKline LLC, Bristol-Myers Squibb Company and ALZA Corp. (acquired by Johnson & Johnson). Additionally, Mr. Huang served on the board of directors of Casi Pharmaceuticals, Inc. from April 2013 to April 2023, Windtree Therapeutics, Inc. from December 2018 to April 2023 and Alaunos Therapeutics, Inc. from July 2020 to September 2023. Currently, Mr. Huang serves as a director on the board of directors of a number of companies, including Kindstar Globalgene Technology, Inc. (9960.HK). He received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
- Kleanthis G. Xanthopoulos
-
Kleanthis G. Xanthopoulos自2020年12月起担任互联生物制药控股有限公司董事会成员。Xanthopoulos博士目前是Irras AB的首席执行官，也是Stork Capital Life Sciences的董事长，Stork Capital Life Sciences专注于创新生物技术公司的建设和投资，Xanthopoulos博士曾于2015年至2020年担任CERUS DMCC的管理普通合伙人。他是生物技术和医药研究领域经验丰富、富有远见的领导者，在运营和企业发展方面有着坚实的基础。他现任Regulus Therapeutics 的总裁、首席执行官、董事。2007年加入 Regulus Therapeutics 之前，他是Enterprise Partners Venture Capital的管理合伙人。他联合创办了Anadys Pharmaceuticals，并于2000-2006年间担任总裁兼首席执行官，在该公司于2011年被罗氏收购之前一直担任董事。在此之前，1997-2000，他担任被Vertex Pharmaceuticals 收购的Aurora Biosciences的副总裁；1995-1997，担任国家人类基因组研究所的部门总监。此前，他是瑞典斯德哥尔摩卡罗林斯卡研究所的副教授在。他现任生物技术工业组织（BIO）、Regulus Therapeutics（纳斯达克代码：RGLS）、 Zosano Pharma的董事会成员，也是Sente, Inc的共同创始人和董事。此外，他获得了2006年安永健康科学年度企业家的荣誉，并于2013年被圣迭戈商业杂志评为最受尊敬的首席执行官。他也是奥纳西斯基金会学者，他获得了希腊塞萨洛尼基亚里士多德大学的生物学荣誉学士学位，瑞典斯德哥尔摩大学的微生物学硕士学位和分子生物学博士学位，以及纽约洛克菲勒大学的博士后研究奖学金。
Kleanthis G. Xanthopoulos,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020 and as Connect Biopharma Holdings Limited Lead Independent Director since January 2022. Dr. Xanthopoulos is currently the Chairman and Chief Executive Officer of Shoreline Biosciences Inc., and Chairman of Stork Capital Life Sciences which focuses on building and investing in innovative biotechnology companies. Dr. Xanthopoulos was Chief Executive Officer of IRRAS AB a publicly traded medical technology company from 2015 to 2021. He was a Managing General Partner at Cerus DMCC, from 2015 to 2020. Previously, he served as President and Chief Executive Officer of Regulus Therapeutics Inc. from the time of its formation in 2007 until June of 2015. Prior to that, he was a Managing Director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. from its inception in 2000 to 2006 and remained a director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Dr. Xanthopoulos also co-founded and served as the first President and Chief Executive Officer of Sente Labs, and a member of the board of Shoreline Biosciences, a cell therapy company, and IRRAS AB. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Prior to this, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. In addition to being a director at Shoreline Biosciences and IRRAS AB, Dr. Xanthopoulos is also a member of the board of directors of Zosano Pharma, Inc and Sente Labs. Dr. Xanthopoulos received his B.S. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos has over 45 peer review publications and several issued patents. - Kleanthis G. Xanthopoulos自2020年12月起担任互联生物制药控股有限公司董事会成员。Xanthopoulos博士目前是Irras AB的首席执行官，也是Stork Capital Life Sciences的董事长，Stork Capital Life Sciences专注于创新生物技术公司的建设和投资，Xanthopoulos博士曾于2015年至2020年担任CERUS DMCC的管理普通合伙人。他是生物技术和医药研究领域经验丰富、富有远见的领导者，在运营和企业发展方面有着坚实的基础。他现任Regulus Therapeutics 的总裁、首席执行官、董事。2007年加入 Regulus Therapeutics 之前，他是Enterprise Partners Venture Capital的管理合伙人。他联合创办了Anadys Pharmaceuticals，并于2000-2006年间担任总裁兼首席执行官，在该公司于2011年被罗氏收购之前一直担任董事。在此之前，1997-2000，他担任被Vertex Pharmaceuticals 收购的Aurora Biosciences的副总裁；1995-1997，担任国家人类基因组研究所的部门总监。此前，他是瑞典斯德哥尔摩卡罗林斯卡研究所的副教授在。他现任生物技术工业组织（BIO）、Regulus Therapeutics（纳斯达克代码：RGLS）、 Zosano Pharma的董事会成员，也是Sente, Inc的共同创始人和董事。此外，他获得了2006年安永健康科学年度企业家的荣誉，并于2013年被圣迭戈商业杂志评为最受尊敬的首席执行官。他也是奥纳西斯基金会学者，他获得了希腊塞萨洛尼基亚里士多德大学的生物学荣誉学士学位，瑞典斯德哥尔摩大学的微生物学硕士学位和分子生物学博士学位，以及纽约洛克菲勒大学的博士后研究奖学金。
- Kleanthis G. Xanthopoulos,has served as a member of Connect Biopharma Holdings Limited board of directors since December 2020 and as Connect Biopharma Holdings Limited Lead Independent Director since January 2022. Dr. Xanthopoulos is currently the Chairman and Chief Executive Officer of Shoreline Biosciences Inc., and Chairman of Stork Capital Life Sciences which focuses on building and investing in innovative biotechnology companies. Dr. Xanthopoulos was Chief Executive Officer of IRRAS AB a publicly traded medical technology company from 2015 to 2021. He was a Managing General Partner at Cerus DMCC, from 2015 to 2020. Previously, he served as President and Chief Executive Officer of Regulus Therapeutics Inc. from the time of its formation in 2007 until June of 2015. Prior to that, he was a Managing Director of Enterprise Partners Venture Capital. Dr. Xanthopoulos co-founded and served as President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. from its inception in 2000 to 2006 and remained a director until its acquisition by Roche in 2011. He was Vice President at Aurora Biosciences (acquired by Vertex Pharmaceuticals, Inc.) from 1997 to 2000. Dr. Xanthopoulos also co-founded and served as the first President and Chief Executive Officer of Sente Labs, and a member of the board of Shoreline Biosciences, a cell therapy company, and IRRAS AB. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Prior to this, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden after completing a Postdoctoral Research Fellowship at The Rockefeller University, New York. In addition to being a director at Shoreline Biosciences and IRRAS AB, Dr. Xanthopoulos is also a member of the board of directors of Zosano Pharma, Inc and Sente Labs. Dr. Xanthopoulos received his B.S. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos has over 45 peer review publications and several issued patents.
高管简历
中英对照 | 中文 | 英文- 郑伟
郑伟是互联生物制药控股有限公司的联合创始人，自2012年成立以来一直担任互联生物制药控股有限公司首席执行官和董事会成员。在此之前，郑伟博士于2007年12月至2011年3月在Arena制药公司担任免疫学主任，负责监督其免疫学发现项目。在此之前，郑伟博士于1998年4月至2007年9月在ChemoCentryx公司担任科学家和项目负责人。在担任这一职务之前，郑伟博士是Glycomed公司的一名科学家，Glycomed公司于1992年9月至1995年11月被Ligand制药公司收购。在加入Glycomed，Inc.之前，郑伟博士还在斯坦福大学医学院进行免疫学研究，郑伟博士在加州大学戴维斯分校获得生物化学和分子生物学博士学位，在华南师范大学获得生物学学士学位。
Zheng Wei,is a co-founder of the company and has served as Connect Biopharma Holdings Limited Chief Executive Officer and a member of Connect Biopharma Holdings Limited board of directors since Connect Biopharma Holdings Limited inception in 2012. Prior to that, Dr. Wei was Director of Immunology at Arena Pharmaceuticals, Inc. from December 2007 to March 2011, where he oversaw its immunology discovery programs. Prior to this role, Dr. Wei was a scientist and program leader at ChemoCentryx, Inc. from April 1998 to September 2007. Prior to this role, Dr. Wei was a scientist at Glycomed, Inc. (acquired by Ligand Pharmaceuticals Incorporated) from September 1992 to November 1995. Before joining Glycomed, Inc., Dr. Wei also conducted immunology research at Stanford University School of Medicine. Dr. Wei received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis and his bachelor's degree in Biology from South China Normal University.- 郑伟是互联生物制药控股有限公司的联合创始人，自2012年成立以来一直担任互联生物制药控股有限公司首席执行官和董事会成员。在此之前，郑伟博士于2007年12月至2011年3月在Arena制药公司担任免疫学主任，负责监督其免疫学发现项目。在此之前，郑伟博士于1998年4月至2007年9月在ChemoCentryx公司担任科学家和项目负责人。在担任这一职务之前，郑伟博士是Glycomed公司的一名科学家，Glycomed公司于1992年9月至1995年11月被Ligand制药公司收购。在加入Glycomed，Inc.之前，郑伟博士还在斯坦福大学医学院进行免疫学研究，郑伟博士在加州大学戴维斯分校获得生物化学和分子生物学博士学位，在华南师范大学获得生物学学士学位。
- Zheng Wei,is a co-founder of the company and has served as Connect Biopharma Holdings Limited Chief Executive Officer and a member of Connect Biopharma Holdings Limited board of directors since Connect Biopharma Holdings Limited inception in 2012. Prior to that, Dr. Wei was Director of Immunology at Arena Pharmaceuticals, Inc. from December 2007 to March 2011, where he oversaw its immunology discovery programs. Prior to this role, Dr. Wei was a scientist and program leader at ChemoCentryx, Inc. from April 1998 to September 2007. Prior to this role, Dr. Wei was a scientist at Glycomed, Inc. (acquired by Ligand Pharmaceuticals Incorporated) from September 1992 to November 1995. Before joining Glycomed, Inc., Dr. Wei also conducted immunology research at Stanford University School of Medicine. Dr. Wei received his Ph.D. in Biochemistry and Molecular Biology from the University of California at Davis and his bachelor's degree in Biology from South China Normal University.
- Steven Chan
Steven Chan自2014年11月起担任公司副总裁和企业总监。加入公司之前，他在Solta Medical, Inc.（一家全球医疗设备公司）担任高级管理职位，从2010年6月到2014年7月担任副总裁和企业总监，负责领先的日常公司范围会计和金融运营。加入Solta Medical之前，2007年6月到2010年6月，他在Moody's Analytics Inc.担任副总裁和财务官；2006年10月到2007年6月担任Polycom全球税收总监；2002年8月到2006年10月担任Logitech International S.A.区域财务总监。他在毕马威会计师事务所（KPMG LLP）开始职业生涯，在公司上升阶段担任过会计和财务相关职位。Chan先生是加利福尼亚州注册会计师，目前处于职业空挡期。他拥有加州大学伯克利分校哈斯商学院企业管理学士学位。
Steven Chan,has served as Connect Biopharma Holdings Limited Chief Financial Officer since November 2021. Previously, Mr. Chan served as Chief Financial Officer at Delphon Industries LLC, a global materials manufacturer, from April 2019 to November 2021. Prior to this role, from April 2017 to April 2019, Mr. Chan was Vice-President, Finance and Corporate Controller at Arcus Biosciences, Inc. Mr. Chan also served as Vice-President, Finance and Corporate Controller at MyoKardia, Inc. from November 2014 to March 2017 and as Vice-President, Corporate Controller at Solta Medical, Inc. from June 2010 to November 2014. Mr. Chan received a B.S. in Business Administration from the University of California at Berkeley, Haas School of Business and is a Certified Public Accountant in California (inactive status).- Steven Chan自2014年11月起担任公司副总裁和企业总监。加入公司之前，他在Solta Medical, Inc.（一家全球医疗设备公司）担任高级管理职位，从2010年6月到2014年7月担任副总裁和企业总监，负责领先的日常公司范围会计和金融运营。加入Solta Medical之前，2007年6月到2010年6月，他在Moody's Analytics Inc.担任副总裁和财务官；2006年10月到2007年6月担任Polycom全球税收总监；2002年8月到2006年10月担任Logitech International S.A.区域财务总监。他在毕马威会计师事务所（KPMG LLP）开始职业生涯，在公司上升阶段担任过会计和财务相关职位。Chan先生是加利福尼亚州注册会计师，目前处于职业空挡期。他拥有加州大学伯克利分校哈斯商学院企业管理学士学位。
- Steven Chan,has served as Connect Biopharma Holdings Limited Chief Financial Officer since November 2021. Previously, Mr. Chan served as Chief Financial Officer at Delphon Industries LLC, a global materials manufacturer, from April 2019 to November 2021. Prior to this role, from April 2017 to April 2019, Mr. Chan was Vice-President, Finance and Corporate Controller at Arcus Biosciences, Inc. Mr. Chan also served as Vice-President, Finance and Corporate Controller at MyoKardia, Inc. from November 2014 to March 2017 and as Vice-President, Corporate Controller at Solta Medical, Inc. from June 2010 to November 2014. Mr. Chan received a B.S. in Business Administration from the University of California at Berkeley, Haas School of Business and is a Certified Public Accountant in California (inactive status).
- 潘武宾
潘武宾是互联生物制药控股有限公司的联合创始人，自2012年5月起担任互联生物制药控股有限公司总裁兼董事会主席。此前，潘博士于2006年6月至2011年10月共同创立并领导了由风险投资支持的合同研究机构Crown Bioscience Inc.。在此任职期间，曾在公司担任多个高管领导职务，包括中国区总裁、首席运营官和执行副总裁，在此之前，潘博士曾于2000年11月至2006年5月在青岛远兴生物制药有限公司担任副总裁。在此之前，潘博士曾于1996年10月至2000年10月在Cubist Pharmaceuticals收购的Terragen Discovery Inc.担任研究科学家。潘博士在苏塞克斯大学获得生物化学博士学位，并在加州大学柏克莱分校完成博士后训练，拥有清华大学硕士学位、中山大学药理学硕士学位和动物学学士学位。
Wubin Pan,is a co-founder of the company and has served as Connect Biopharma Holdings Limited President and Chairperson of Connect Biopharma Holdings Limited board of directors since May 2012. Previously, Dr. Pan co-founded and led Crown Bioscience Inc., a venture-backed contract research organization, from June 2006 to October 2011. During this tenure, he served in various executive leadership positions at the company, including PRC President, Chief Operation Officer and Executive Vice President. Prior to this role, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. from November 2000 to May 2006. Prior to that, Dr. Pan worked as a research scientist with TerraGen Discovery Inc. (acquired by Cubist Pharmaceuticals) from October 1996 to October 2000. Dr. Pan obtained his Ph.D. in Biochemistry from University of Sussex and completed postdoctoral training at the University of California at Berkeley. He holds an M.B.A. from Tsing-Hua University and an M.S. in Pharmacology and a B.S. in Zoology, both from Sun Yat-sen University.- 潘武宾是互联生物制药控股有限公司的联合创始人，自2012年5月起担任互联生物制药控股有限公司总裁兼董事会主席。此前，潘博士于2006年6月至2011年10月共同创立并领导了由风险投资支持的合同研究机构Crown Bioscience Inc.。在此任职期间，曾在公司担任多个高管领导职务，包括中国区总裁、首席运营官和执行副总裁，在此之前，潘博士曾于2000年11月至2006年5月在青岛远兴生物制药有限公司担任副总裁。在此之前，潘博士曾于1996年10月至2000年10月在Cubist Pharmaceuticals收购的Terragen Discovery Inc.担任研究科学家。潘博士在苏塞克斯大学获得生物化学博士学位，并在加州大学柏克莱分校完成博士后训练，拥有清华大学硕士学位、中山大学药理学硕士学位和动物学学士学位。
- Wubin Pan,is a co-founder of the company and has served as Connect Biopharma Holdings Limited President and Chairperson of Connect Biopharma Holdings Limited board of directors since May 2012. Previously, Dr. Pan co-founded and led Crown Bioscience Inc., a venture-backed contract research organization, from June 2006 to October 2011. During this tenure, he served in various executive leadership positions at the company, including PRC President, Chief Operation Officer and Executive Vice President. Prior to this role, Dr. Pan was the Vice President at TsingHuaYuanXing Biopharmaceutical Co. Ltd. from November 2000 to May 2006. Prior to that, Dr. Pan worked as a research scientist with TerraGen Discovery Inc. (acquired by Cubist Pharmaceuticals) from October 1996 to October 2000. Dr. Pan obtained his Ph.D. in Biochemistry from University of Sussex and completed postdoctoral training at the University of California at Berkeley. He holds an M.B.A. from Tsing-Hua University and an M.S. in Pharmacology and a B.S. in Zoology, both from Sun Yat-sen University.